Survey on the interaction effect of dopamine D2 receptor antagonist on morphine-induced polycystic ovary syndrome in rat

Document Type : Original Article

Authors

Abstract

Background and Objective: Polycystic ovary syndrome (PCOS) is one of the most common endocrine and metabolic disorders in premenopausal women. Opioid drugs, including morphine are effective inducers of the PCOS. Hyperprolactinemia also increases the likelihood of this complication. The dopamine, the inhibitor of prolactin secretion, has receptors in the ovarian tissue. In this study, metoclopramide was used as a dopamine receptor antagonist (D2) to survey the interaction of dopamine with morphine.
Materials and Methods: 48 female Wistar rats were studied as virgins (and under the diestrus phase) in the weight range of 220-250 g. The first group received morphine (5 mg/kg) intraperitoneally. The second to fourth groups received metoclopramide (1, 2, 4 mg/kg). In groups 5 to 7, the antagonist (1, 2, 4 mg/kg) with morphine (5 mg/kg) was injected over a period of 20 minutes. The control group received only saline (1 ml/kg). Forty-eight hours after drug administration, the animals underwent surgery and the ovaries and uterus were examined. Statistical analysis was performed by analysis of variance.
Results: The ovaries showed a polycystic view in the morphine group. There were no cystic structures in the metoclopramide groups, but the number of ovarian cysts increased in the metoclopramide+morphine recipient groups. There was a relative increase in uterine diameter due to morphine injection which returned in combination with the antagonist.
Conclusion: Metoclopramide may have increased morphine-induced cystogenesis in the ovary by inhibiting dopamine receptors and increasing the prolactin effect.

Keywords

References

  1. Johnson JH, Rosecrans JA. Blockade of ovulation by methadone in the rat: a centralnervous system mediated acute effect. The Journal of Pharmacology and Experimental Therapeutics 1980; 213(1):110.
  2. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbons: hormonal and metabolic profile. Journal of Clinical Endocrinology and Metabolism 1999; 84:4006-11.
  3. Dunaif A, Polycystic ovary syndrome in 2011: genes, aging and sleep apnea in polycystic ovary syndrome. Nature Reviews Endocrinology 2011;20:72-4.
  4. Creatsas G, Koliopoulos C, Mastorakos G. Combined oral contraceptive treatment of adolescent girls with polycystic ovary syndrome. Lipid Profile. The Annals of the New York Academy of Sciences 2000; 900:245-52.
  5. Siddiqui A, Haq S, Shah BH. Prenatal exposure to morphine disrupts brain norepinephrine, ovarian cyclicity and sexual respectivity in rats. Pharmacology Biochemistry and Behavior 1997; 58(1):243-248.
  6. Van Ree JM, Gerrits MA, Vanderschuren LJ. Opioids, reward and addiction: an encounter of biology, psychology, and medicine. Pharmacological Reviews 1999; 51(2): 341-396.
  7. Katzung BG, Masters SB, Trevor AJ. Basic and clinical pharmacology. Vol. 8 Toronto: Lange Medical Books/McGraw-Hill 2001.
  8. Lembo PM, Grazzini E, Groblewski T, O'Donnell D, Roy MO, Zhang J, et al. Proenkephalin A gene products activate a new family of sensory neuron-specific GPCRs. Nature Neuroscience 2002; 5(3):201-209.
  9. Gear RW, Miaskowski C, Gordon NC, Paul SM, Heller PH, Levine JD. Kappa–opioids produce significantly greater analgesia in women than in men. Nature Medicine 1996; 2(11):1248-1250.
  10. Van Ree JM, Gerrits MA, Vanderschuren LJ. Opioids, reward and addiction: an encounter of biology, psychology, and medicine. Pharmacological Reviews 1999; 51(2):341-96
  11. Mahmoudian A, Dehghan M, Jafarpour M. The effect of morphine administration on structure and ultrastructure of uterus in pregnant mice. Iranian Journal of Reproductive Medicine 2010; 8:111-8.
  12. Xita, N, Tsatsoulis A. Fetal Programming of Polycystic Ovary Syndrome by Androgen Excess: Evidence from Experimental, Clinical, and Genetic Association Studies. Journal of Clinical Endocrinology and Metabolism 2006; 91(5):1660-6.
  13.  Gallinelli A, Ciaccio I, Giannella L, Salvatori M, Marsella T, Volpe A. Correlations between concentrations of interleukin-12 and interleukin-13 and lymphocyte subsets in the follicular fluid of women with and without polycystic ovary syndrome. Fertility and Sterility 2003; 79(6):1365-72.
  14. Smith YR, Stohler CS, Nichols TE, Bueller JA, Koeppe RA, Zubieta JK. Pronociceptive and antinociceptive effects of estradiol through endogenous opioid neurotransmission in women. The Journal of Neuroscience 2006; 26(21):5777-85.
  15. Eyvazzadeh AD, Pennington KP, Pop-Busui of the endogenous opioid system in polycystic ovary syndrome. Fertility and Sterility 2009; 92(1):1-12.
  16. Dehghan M, Jafarpour M, Mohmoudian A. The effect of morphine administration on structure and ultrastucture of uterus in pregnant mice. Iranian Journal of Reproductive Medicine 2010; 8(3):111-8.
  17. Shariff J, Olsom L. Hormonal regulation of nitric oxide synthase and their cell specific Expression during Follicular Development in the rat ovary I. Endocrinology 1997; 138(1):460-8.
  18. Gomes RCT, Verna C, Simoes RS, Wolff RB, Baracat EC,  Soares-Jr JM. Baracat; José Maria Soares-Jr. Effects of metoclopramide on the mouse anterior pituitary during the estrous cycle. Federal University of São Paulo 2011; 66(6):1101-04.
  19. Deyo SN, Swift RM,  Miller FJ. Morphine and endorphins modulate dopamine turnover in rat median eminence. Proceedings of the National Academy of Sciences of the United States of America 1979; 76:3006-9.
  20. Ferland L, Fuxe K, Eneroth P, Gustafsson JA, Skett P. Effects of methionine enkephalin on prolactin release and catecholamine levels and turnover in the median eminence. European Journal of Pharmacology 1977; 43:89-90.
  21. Grosvener CE, Goodman GT, Mena F. Control of the multiphase secretion of prolactin in the lactating rat. In: Mena F and Valverde-R C. (Eds.), Prolactin Secretion A Multidisciplinao' Approach. Academic, New York 1984: 275.
  22. Darban Fooladi M, Karami M,  Jalali Nadoushan MR,  Lakzaei F. Ovarian Polycystic Induction with Morphine in Wistar Rat. Journal of Basic and Clinical Pathophysiology 2014-2015; 3(1):1-6.
  23. Lopes IMRS, Baracat MCP, JesusSimões M, SantosSimões R, Baracat EC, Soares JM. Endometrium in women with polycystic ovary syndrome during the window of implantation. Revista da Associação Médica Brasileira (English Edition) 2011; 57(6):688-95.
  24. Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R et al. Diagnosis and treatment of polycystic ovary syndrome: an endocrine society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 2013; 98(12):4565-92.
  25. Gomes RCT, Verna C, Simoes RS, Wolff RB, Baracat EEC, Soares-Jr JM. Effects of metoclopramide on the mouse anterior pituitary during the estrous cycle. Federal University of São Paulo 2011; 66(6):1101-04.
  26. Freeman ME, Kanyicska B, Lerant A, Nagy G. Prolactin: structure, function, and regulation of secretion. Physiological Reviews 2000; 80:1523-1631.
  27. Dubey PK, Sharma GT. Nitric Oxide and Ovarian Folliculogenesis: A Possible Role in Follicular Atresia-A Review 2016.
  28. Cella M, Farina MG, Dominguez Rubio AP, Girolamo GD, Ribeiro ML, Franchi AM. Dual effect of nitric oxide on uterine prostaglandin synthesis in amurine model of preterm labour. British Journal of Pharmacology 2010; 161:844-55.
Daneshvar Medicine
Volume 28, Issue 3 - Serial Number 148
July and August 2020
Pages 16-27

Files

Share

How to cite

Statistics